Effect of Nicotinamide Adenine Dinucleotide on Heart Failure Caused by Ischemic Cardiomyopathy: A Randomized, Placebo-Controlled Trial.

ABSTRACT:

Background

Nicotinamide adenine dinucleotide (NAD+) is a fundamental coenzyme that plays a crucial role in cellular energy metabolism and redox homeostasis. A deficiency in NAD+ has been associated with heart failure (HF), which often occurs in the advanced stages of cardiovascular diseases. While numerous studies have indicated that NAD+ supplementation may enhance cardiac bioenergetics and function in animal models, there is limited research investigating this potential effect in human patients. Therefore, this study aims to evaluate whether NAD+ treatment can lead to improved clinical outcomes for patients with HF due to ischemic cardiomyopathy (ICM).

Methods

This single-center, prospective, randomized, placebo-controlled trial enrolled 180 adults diagnosed with ICM whose

SUBMITTER: Yu X 

PROVIDER: S-EPMC12779688 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature